Berns Paul L's Form 4 filing
Lyell Immunopharma, Inc. (LYEL) · filed Mar 9, 2026
- Accession no.
- 0001012975-26-000234
- Filed
- Mar 9, 2026, 4:34 PM ET
- Trade date
- Mar 6, 2026
- Filing delay
- 3 days
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction. Open-market purchases total $12.5M. It was filed 3 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Berns Paul LCIK 0001202769 | 10% Owner |
| Crandell KeithCIK 0001219039 | 10% Owner |
| Nelsen RobertCIK 0001219042 | 10% Owner |
| Bybee ClintonCIK 0001219043 | 10% Owner |
| Gillis StevenCIK 0001229592 | 10% Owner |
| Burow KristinaCIK 0001569248 | 10% Owner |
| ARCH Venture Fund XIII, L.P.CIK 0002006772 | 10% Owner |
| ARCH Venture Partners XIII, LLCCIK 0002016082 | 10% Owner |
| ARCH Venture Partners XIII, L.P.CIK 0002016083 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 6, 2026 | Common Stock | PPurchaseAcquired | +488,090 | $25.61 | +$12,499,984.9 | 1,426,528 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.
Remarks
This Form 4 is one of two reports relating to the same transaction being filed jointly by ARCH Venture Partners XIII, LLC, ARCH Venture Partners XIII, L.P., ARCH Venture Fund XIII, L.P., Keith Crandell, Robert Nelsen, Kristina Burow, Steven Gillis, Paul Berns, Clinton Bybee, ARCH Venture Partners IX, LLC, ARCH Venture Partners IX, L.P., ARCH Venture Partners IX Overage, L.P., ARCH Venture Fund IX, L.P. and ARCH Venture Fund IX Overage, L.P.